Search

Displaying results 3731 - 3740 of 6835 in total
  1. Drug

    Gamolenic acid

    go.drugbank.com/drugs/DB13854
    ApprovedWithdrawn

    It is converted to [DB00154], a biosynthetic precursor of monoenoic prostaglandins such as PGE1. … It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6; 6,9,12-octadecatrienoic acid; and cis-6, cis-9, cis-12- octadecatrienoic acid [F27].

  2. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

  3. Drug

    Talsupram

    go.drugbank.com/drugs/DB09191
    Experimental

    It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].

  4. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  5. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’ … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.

  6. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551]. … H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551].

  7. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    It releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity. … [A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this

  8. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).

  9. Drug

    Ethoheptazine

    go.drugbank.com/drugs/DB08988
    ApprovedWithdrawn

    It was invented in the 1950s and is related to other drugs such as proheptazine. Ethoheptazine is no longer marketed in the United States.

  10. Drug

    Atazanavir

    go.drugbank.com/drugs/DB01072
    ApprovedInvestigational

    Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV).